An experimental gene therapy designed to "reprogram" older cells and restore more youthful biological traits has entered its first clinical trial in humans, according to a Fox News report. The approach, known as cellular reprogramming, is intended to affect the biological age of cells rather than chronological age.
Researchers hope the technology will first help treat age-related diseases, especially a condition linked to reduced vision in older adults. The first patient in the trial has already received the treatment, and the study is currently focused mainly on safety and on measuring any effect on the eye disease.
The broader scientific idea is that a person's chronological age does not necessarily reflect health status. Scientists are increasingly studying biological age in cells and tissues, which is shaped by genetics, environment, and lifestyle, in hopes of preserving normal organ function longer and extending healthy years of life.
Dr. Gabriel Lyon told Fox News that the development is intriguing in longevity medicine, but stressed that it remains at an early research stage and that there is no proof yet that the treatment can slow or reverse aging in humans. Experts said the path from a clinical trial to an approved therapy is still long, requiring more data on safety, effectiveness, and long-term effects. Still, the move from lab work to human testing is seen as a major milestone. If future results are positive, the technology could eventually be used against more age-related illnesses. For now, proven advice remains regular exercise, a balanced diet, good sleep, and avoiding smoking.
